The Newest Hep-C Partnership

Before you go, we thought you'd like these...
Before you go close icon

In this video, Motley Fool health-care analyst David Williamson looks at the newest hepatitis C partnership, this time between small biotech Idenix and big pharma Johnson & Johnson. The race is on to create a cure using a combination of the next generation of interferon-free drugs, and the companies without all the parts for a viable cocktail are frantically teaming up to gain traction before it is too late. Watch to find out what this newest collaboration means for investors in both companies.

In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. It offers everything from baby powder to biologics, and critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand-new premium report on Johnson & Johnson. To claim your copy, simply click here now for instant access.

 

The article The Newest Hep-C Partnership originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow him on Twitter: @MotleyDavidThe Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners